Avestar Capital’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-2,000
Closed -$286K 304
2022
Q2
$286K Hold
2,000
0.07% 217
2022
Q1
$345K Buy
+2,000
New +$337K 0.06% 281
2021
Q4
Sell
-3,000
Closed -$1.16M 479
2021
Q3
$1.16M Buy
+3,000
New +$1.11M 0.15% 162

Other funds holding MRNA

Avestar Capital's MRNA Position: Q3 2024 in Review

Avestar Capital sold out of Moderna (MRNA) in Q3 2024, closing a stake of 2,495 shares — an estimated $296K sold.

Avestar Capital first reported a position in MRNA in Q3 2020 and held it in 9 quarters. The position peaked at $2.42M in Q3 2021. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Avestar Capital reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Avestar Capital sold 2,495 Moderna shares in Q3 2024, an estimated $296K.
  • Avestar Capital first reported a position in Moderna in Q3 2020 and held it in 9 quarters.
  • Avestar Capital's Moderna position peaked at $2.42M in Q3 2021.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Avestar Capital's 13F filing for Q3 2024, filed 13 Nov 2024.